FOR LABORATORY RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTION
WOLVERINEGIGARESEARCH

WOLVERINE · SUBTOPIC · SAFETY PROFILE

WOLVERINE Safety Profile

For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of WOLVERINE.

OBSERVED ADVERSE EVENTS IN LITERATURE

The following adverse events have been observed in trials or animal studies of WOLVERINE. Severity, frequency, and attribution depend on the source publication.

  • Inherits side-effect profiles of all three components

DRUG INTERACTIONS

The following interactions are reported in or theorised from the published mechanism for WOLVERINE.

  • Per-component interactions apply

CONTRAINDICATIONS REPORTED IN LITERATURE

Contraindications recorded for WOLVERINE in the published record:

  • Active malignancy (theoretical · all three components are pro-angiogenic)
  • Pregnancy/lactation (unstudied)

FDA REGULATORY STATUS

Not FDA-approved as a combined product. Per-component status varies. BPC-157 is on FDA Category 2 of the 503A bulks list.

WADA REGULATORY STATUS

BPC-157 prohibited under S0. TB-500 prohibited under S2. GHK-Cu not listed.

SAFETY Q+A FROM LITERATURE

Is Wolverine blend FDA-approved?

No. None of the three component peptides is FDA-approved for any human therapeutic use under this combinatorial label. Research-grade material is supplied for laboratory use only.

Is Wolverine blend banned in sports?

Two of three components are WADA-prohibited: BPC-157 (S0 non-approved substances) and TB-500 (S2 peptide hormones/growth factors). GHK-Cu is not listed. The blend should be assumed prohibited in competition.

CITED LITERATURE

The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.

  • Sikiric P et al.. BPC-157 stable gastric pentadecapeptide (cytoprotection review). Inflammopharmacology 2024. PMID 38980576. link
  • Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 / TB-500 active sites. FASEB J 2010. PMID 20179146. link
  • Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 2008. PMID 18644225. link

RELATED PAGES

WOLVERINE OVERVIEWMECHANISM ▶DOSING LITERATURE ▶

▶ LAST UPDATED · 2026-05-19

© 2026 GigaCompounds LLC · For Laboratory Research Use Only